FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2623304866> ?p ?o ?g. }

• W2623304866 endingPage "377" @default.
• W2623304866 startingPage "369" @default.
• W2623304866 abstract "CT-P10 is a biosimilar candidate of innovator rituximab (RTX) that demonstrated a comparable clinical profile to RTX in a phase I randomized controlled trial (RCT) in rheumatoid arthritis (RA) (ClinicalTrials.gov identifier: NCT01534884). This open-label extension (OLE) study (NCT01873443) compared the efficacy and safety of CT-P10 in patients with RA who received CT-P10 from the outset (i.e., from the start of the RCT and also in the OLE; ‘maintenance group’) with those who received RTX during the RCT and switched to CT-P10 during the OLE (‘switch group’). Patients who completed the RCT were recruited. Based on the Disease Activity Score using 28 joints (DAS28) and predefined safety criteria, patients could receive up to two courses of CT-P10 during the OLE. Efficacy [DAS28 and European League Against Rheumatism (EULAR) response], safety and immunogenicity were assessed. Eighty-seven patients were enrolled; 58 and 29 had previously received CT-P10 or RTX, respectively, in the RCT. Of these, 38 (65.5%) and 20 (69.0%) were treated with CT-P10 in the OLE and therefore comprised the maintenance and switch groups, respectively. The mean change in DAS28-erythrocyte sedimentation rate (ESR) from baseline (week 0 of RCT) at week 24 of the first OLE treatment course in the maintenance and switch groups was −2.7 and −2.4, respectively. The proportion of patients with good/moderate EULAR responses was also comparable between groups. Antidrug antibodies were detected in 13.2 and 15.0% of patients in the maintenance and switch groups, respectively, at week 24 of the first OLE course. CT-P10 treatment was well-tolerated when administered for up to 2 years or after switching from RTX. In this study population, comparable efficacy and safety profiles were observed in patients who switched from RTX to CT-P10 and those maintained on CT-P10 throughout treatment." @default.
• W2623304866 created "2017-06-15" @default.
• W2623304866 creator A5003254047 @default.
• W2623304866 creator A5004670805 @default.
• W2623304866 creator A5005038120 @default.
• W2623304866 creator A5005854939 @default.
• W2623304866 creator A5007364793 @default.
• W2623304866 creator A5008545401 @default.
• W2623304866 creator A5030599616 @default.
• W2623304866 creator A5032940273 @default.
• W2623304866 creator A5035577773 @default.
• W2623304866 creator A5036530922 @default.
• W2623304866 creator A5057669105 @default.
• W2623304866 creator A5064191889 @default.
• W2623304866 creator A5064707258 @default.
• W2623304866 creator A5066408904 @default.
• W2623304866 creator A5072419462 @default.
• W2623304866 creator A5076575654 @default.
• W2623304866 creator A5082275964 @default.
• W2623304866 creator A5086477416 @default.
• W2623304866 creator A5089561583 @default.
• W2623304866 creator A5090693306 @default.
• W2623304866 date "2017-06-09" @default.
• W2623304866 modified "2023-10-14" @default.
• W2623304866 title "Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis" @default.
• W2623304866 cites W1807438491 @default.
• W2623304866 cites W1967570746 @default.
• W2623304866 cites W1968889356 @default.
• W2623304866 cites W2000905503 @default.
• W2623304866 cites W2009303541 @default.
• W2623304866 cites W2040867432 @default.
• W2623304866 cites W2065055449 @default.
• W2623304866 cites W2077882848 @default.
• W2623304866 cites W2106997293 @default.
• W2623304866 cites W2110177517 @default.
• W2623304866 cites W2133205391 @default.
• W2623304866 cites W2135856630 @default.
• W2623304866 cites W2140790130 @default.
• W2623304866 cites W2142004396 @default.
• W2623304866 cites W2342464058 @default.
• W2623304866 cites W2345220764 @default.
• W2623304866 cites W2519049669 @default.
• W2623304866 cites W3006080604 @default.
• W2623304866 doi "https://doi.org/10.1007/s40259-017-0233-6" @default.
• W2623304866 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5548826" @default.
• W2623304866 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28600696" @default.
• W2623304866 hasPublicationYear "2017" @default.
• W2623304866 type Work @default.
• W2623304866 sameAs 2623304866 @default.
• W2623304866 citedByCount "39" @default.
• W2623304866 countsByYear W26233048662017 @default.
• W2623304866 countsByYear W26233048662018 @default.
• W2623304866 countsByYear W26233048662019 @default.
• W2623304866 countsByYear W26233048662020 @default.
• W2623304866 countsByYear W26233048662021 @default.
• W2623304866 countsByYear W26233048662022 @default.
• W2623304866 countsByYear W26233048662023 @default.
• W2623304866 crossrefType "journal-article" @default.
• W2623304866 hasAuthorship W2623304866A5003254047 @default.
• W2623304866 hasAuthorship W2623304866A5004670805 @default.
• W2623304866 hasAuthorship W2623304866A5005038120 @default.
• W2623304866 hasAuthorship W2623304866A5005854939 @default.
• W2623304866 hasAuthorship W2623304866A5007364793 @default.
• W2623304866 hasAuthorship W2623304866A5008545401 @default.
• W2623304866 hasAuthorship W2623304866A5030599616 @default.
• W2623304866 hasAuthorship W2623304866A5032940273 @default.
• W2623304866 hasAuthorship W2623304866A5035577773 @default.
• W2623304866 hasAuthorship W2623304866A5036530922 @default.
• W2623304866 hasAuthorship W2623304866A5057669105 @default.
• W2623304866 hasAuthorship W2623304866A5064191889 @default.
• W2623304866 hasAuthorship W2623304866A5064707258 @default.
• W2623304866 hasAuthorship W2623304866A5066408904 @default.
• W2623304866 hasAuthorship W2623304866A5072419462 @default.
• W2623304866 hasAuthorship W2623304866A5076575654 @default.
• W2623304866 hasAuthorship W2623304866A5082275964 @default.
• W2623304866 hasAuthorship W2623304866A5086477416 @default.
• W2623304866 hasAuthorship W2623304866A5089561583 @default.
• W2623304866 hasAuthorship W2623304866A5090693306 @default.
• W2623304866 hasBestOaLocation W26233048662 @default.
• W2623304866 hasConcept C126322002 @default.
• W2623304866 hasConcept C168563851 @default.
• W2623304866 hasConcept C197934379 @default.
• W2623304866 hasConcept C198451711 @default.
• W2623304866 hasConcept C2777489490 @default.
• W2623304866 hasConcept C2777575956 @default.
• W2623304866 hasConcept C2778143017 @default.
• W2623304866 hasConcept C2779338263 @default.
• W2623304866 hasConcept C2780653079 @default.
• W2623304866 hasConcept C59491497 @default.
• W2623304866 hasConcept C71924100 @default.
• W2623304866 hasConcept C90924648 @default.
• W2623304866 hasConceptScore W2623304866C126322002 @default.
• W2623304866 hasConceptScore W2623304866C168563851 @default.
• W2623304866 hasConceptScore W2623304866C197934379 @default.
• W2623304866 hasConceptScore W2623304866C198451711 @default.
• W2623304866 hasConceptScore W2623304866C2777489490 @default.
• W2623304866 hasConceptScore W2623304866C2777575956 @default.
• W2623304866 hasConceptScore W2623304866C2778143017 @default.

• next